New radioactive therapy targets mysterious cancers
NCT ID NCT07434180
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests a new radioactive drug, Lu-177 FAP-2286, in 20 patients with cancer of unknown primary (CUP). The drug targets a protein found on cells near tumors, delivering radiation directly to the cancer. The main goal is to see if the treatment can shrink tumors or stop them from growing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Lu-177 FAP-2286 (a radioactive drug that targets cancer cells)
- What this could lead to
- If successful, this could offer a new treatment option for patients with cancer of unknown primary, potentially shrinking tumors and delaying disease progression.
- What could go wrong
- This is a small, early-phase trial with only 20 participants, so results may not apply to everyone. The treatment involves radiation, which can cause side effects, and it is not yet known if it will be effective.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER OF UNKNOWN PRIMARY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peter MacCallum Cancer Centre
Melbourne, Victoria, 3000, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.